Penetration of Cefotaxime into Bronchial Secretions

Study of the Diffusion of Cefmenoxime into the Bronchial Secretions

“…In group 11 (3 g of cefmenoxime admin istered over a period of 2 days), the anti biotic concentrations in the bronchial se cretions were not lower than in group I, in contrast with other studies [3,6] showing a decrease of bronchial levels after multiple doses, probably because in this particular study, the administration of multiple doses was too short to observe a decrease in the bronchial inflammation. The bronchial concentrations varied from patient to pa tient possibly in relation to the variable de gree of inflammation of the bronchial tis sues, the variable and unknown volume of the bronchial secretions, the weight of the patients and the variable underlying disease.…”

“…One observes a certain variability in the concentrations measured in the bronchial secretions which is usually observed with /3-lactam antibiotics according to previous studies [2,3,6].…”

“…The measurement of cefmenoxime in bronchial secretions at various times showed that this antibiotic enters slowly into the bronchial lumen; the mean bron chial peak was achieved after 2 h, as is usual for cephalosporins [2,3].…”

Pulmonary Bacterial Infections in the Immunocompromised Host

“…Comparison of sputum concentrations of ceftotaxime and ceftazidime and the in vitro activity of these antibiotics against Pseudomonas aeruginosa and Escherichia coli. 52,53 appear relatively comparable to those achieved with combined beta-lactam antibiotic-aminoglycoside therapy in nonbacteremic patients. However, because the number of bacteremic infections is not known, these data cannot be generalized to the most critically ill patients with these infections.…”

“…Figure 2 compares the peak concentration of two third generation cephalosporins in the bronchial secretions in comparison to the concentration of antibiotic that inhibits 90% of the strains (MIC 90 ) of E. coli and P. aeruginosa. 52,53 Both agents have bronchial secretion concentrations more than fivefold greater than the in vitro centrations more than fivefold greater than the in vitro MIC 90 for E. coli; yet although ceftazidime is perhaps the most active of the new cephalosporins against P. aeruginosa, the MIC 90 of this organism is well above the bronchial concentration of the antibiotic.…”